February 22, 2021 February 23, 2021 February 24, 2021 February 25, 2021 February 26, 2021

Program

10 - Working Group

Ärztlicher Beirat DHG

9:00 a.m. - 10:30 a.m.

11 - Master Class

Master Class: Hemostasis in critical care

9:00 a.m. - 10:00 a.m.

12 - Master Class

Master Class: Lab testing of anticoagulants in everyday practice

10:00 a.m. - 11:00 a.m.

13 - Master Class

Master Class: Diagnosis of venous thromboembolic disease

11:00 a.m. - 12:00 p.m.

14 - Master Class

Master Class: Diagnosis and management of heparin-induced thrombocytopenia

11:00 a.m. - 12:00 p.m.

15 - Satellite Symposium

Novo Nordisk Pharma GmbH

12:00 p.m. - 1:30 p.m.

16 - Satellite Symposium

Alexion Pharma Germany GmbH

12:00 p.m. - 1:30 p.m.

17 - Satellite Symposium

CSL Behring GmbH

12:00 p.m. - 1:30 p.m.

18 - Oral Communication

Cancer-associated Thrombophilia

1:45 p.m. - 3:15 p.m.

19 - Oral Communication

Cardiology & Neurology

1:45 p.m. - 3:15 p.m.

20 - Oral Communication

Progress in Hemophilia Treatment

1:45 p.m. - 3:15 p.m.

21 - Plenary

Plenary 1 - T&H Across Borders

3:30 p.m. - 4:30 p.m.

22 - State of the Art

Hemophilia

4:45 p.m. - 6:15 p.m.

23 - State of the Art

Hemato-oncology A

4:45 p.m. - 6:15 p.m.

24 - State of the Art

News on Platelets

4:45 p.m. - 6:15 p.m.

25 - State of the Art

Cardiology - Neurology

4:45 p.m. - 6:15 p.m.

26 - State of the Art

Drug discovery

4:45 p.m. - 6:15 p.m.

27 - Satellite Symposium

Alexion Pharma Germany GmbH

6:30 p.m. - 8:00 p.m.

28 - Satellite Symposium

LEO Pharma GmbH

6:30 p.m. - 8:00 p.m.

29 - Satellite Symposium

BioMarin Deutschland GmbH

6:30 p.m. - 8:00 p.m.

Plenary

State of the Art

Oral Communication

Symposium

Workshop

Master Class

Working Group

Miscellaneous

Events

10 - Working Group

Ärztlicher Beirat DHG

9:00 a.m. - 10:30 a.m., External session 2

10 - Working Group

Ärztlicher Beirat DHG

9:00 a.m. - 10:30 a.m., External session 2

11 - Master Class

Master Class: Hemostasis in critical care

9:00 a.m. - 10:00 a.m., External session

Tutor: Wolfgang Korte (St. Gallen)

The Master Classes take place outside the congress platform, by pre-registration. The access data for the session will be sent to all registered participants a few days in advance.

11 - Master Class

Master Class: Hemostasis in critical care

9:00 a.m. - 10:00 a.m., External session

12 - Master Class

Master Class: Lab testing of anticoagulants in everyday practice

10:00 a.m. - 11:00 a.m., External session

Tutor: Isabelle Gouin-Thibault (Rennes), Francois Mullier (Yvoir)

The Master Classes take place outside the congress platform, by pre-registration. The access data for the session will be sent to all registered participants a few days in advance.

12 - Master Class

Master Class: Lab testing of anticoagulants in everyday practice

10:00 a.m. - 11:00 a.m., External session

13 - Master Class

Master Class: Diagnosis of venous thromboembolic disease

11:00 a.m. - 12:00 p.m., External session

Tutor: Marc Righini (Geneva)

The Master Classes take place outside the congress platform, by pre-registration. The access data for the session will be sent to all registered participants a few days in advance.

13 - Master Class

Master Class: Diagnosis of venous thromboembolic disease

11:00 a.m. - 12:00 p.m., External session

14 - Master Class

Master Class: Diagnosis and management of heparin-induced thrombocytopenia

11:00 a.m. - 12:00 p.m., External session 2

Tutor: Yves Gruel (Tours)

The Master Classes take place outside the congress platform, by pre-registration. The access data for the session will be sent to all registered participants a few days in advance.

14 - Master Class

Master Class: Diagnosis and management of heparin-induced thrombocytopenia

11:00 a.m. - 12:00 p.m., External session 2

15 - Satellite Symposium

Novo Nordisk Pharma GmbH

12:00 p.m. - 1:30 p.m., Rome

Chair: Carmen Escuriola-Ettingshausen (Mörfelden-Walldorf), Inga Hegemann (Zurich)

VII – VIII – IX – Klinische Entscheidungen beruhen auf Erfahrungen. Das Symposium mit Erfahrungsaustausch

Entscheidung für N8-GP oder N9-GP bei Kindern: Erfahrungen aus der Schweiz*

Heinz Hengartner, St. Gallen
Erfahrung entscheidet: N8-GP und N9-GP bei chirurgischen Eingriffen

Georg Goldmann, Bonn
Sicher entscheiden bei erworbener Hämophilie: Neue Empfehlungen und Daten

Andreas Tiede, Hannover

* N8-GP und N9-GP sind im Geltungsbereich der Zentralen Europäischen Zulassung (u.a. Deutschland und Österreich) für Patienten im Alter von 12 Jahren und älter zugelassen. In der Schweiz sind N8-GP und N9-GP für vorbehandelte Patienten ab 0 Jahren zugelassen.

15 - Satellite Symposium

Novo Nordisk Pharma GmbH

12:00 p.m. - 1:30 p.m., Rome

16 - Satellite Symposium

Alexion Pharma Germany GmbH

12:00 p.m. - 1:30 p.m., Barcelona

Chair: Florian Langer (Hamburg)

Thrombosen und thrombotische Mikroangiopathien - wenn das Komplement sich einmischt

Thrombozytopenie mit Hämolyse und Nierenbeteiligung – wann an aHUS denken?

Thorsten Feldkamp, Hannoversch Münden
Seltene Thrombosen, schon mal an PNH gedacht?

Florian Langer, Hamburg
Die C5-Komplementinhibition geht in die nächste Runde!

Alexander Röth, Essen
Diskussion

16 - Satellite Symposium

Alexion Pharma Germany GmbH

12:00 p.m. - 1:30 p.m., Barcelona

17 - Satellite Symposium

CSL Behring GmbH

12:00 p.m. - 1:30 p.m., Sydney

Chair: Karin Kurnik (Munich)

Gerinnung bleibt spannend - von Covid-19 zur Gentherapie

Covid-19 und Gerinnungsstörungen: Hämophilie/VWS

Florian Langer, Hamburg
IDELVION - neue klinische Daten

Johannes Oldenburg, Bonn
AFSTYLA – eine langwirksame Option in der Hämophilie A

Martin Olivieri, München
AFSTYLA – Kasuistik (OP)

Kathrin Dengler, Bremen
AFSTYLA – Kasuistik (Prophylaxe)

Georg Goldmann, Bonn
Gentherapie in der Hämophilie – was ist relevant aus Patientensicht?

Robert Klamroth, Berlin
Diskussion

17 - Satellite Symposium

CSL Behring GmbH

12:00 p.m. - 1:30 p.m., Sydney

18 - Oral Communication

Cancer-associated Thrombophilia

1:45 p.m. - 3:15 p.m., Rome

Chair: Corinne Frère (Paris), Jan-Dirk Studt (Zurich)

1
Development and validation of machine learning predictive models applying for cancer-associated deep vein thrombosis: A 1035-sample retrospective cohort study

S. Jin, D. Qin, B. S. Liang, L. C. Zhang, X. X. Wei, Y. J. Wang, B. Zhuang, T. Zhang, Z. P. Yang, Y. W. Cao, S. L. Jin, P. Yang, B. Jiang, B. Q. Rao, H. P. Shi, Q. Lu, Presenter: S. Jin (Beijing)
2
Modelization the impact of antithrombotic agents on pancreatic tumoral micro-environment.

H. Tran¹, R. Amrane¹, E. Mbemba¹, M. Sabbah¹, P. Vandreden^{2, 1}, G. Gerotziafas¹, Presenter: H. Tran¹ (¹Paris, ²Gennevilliers)
3
Aggressiveness of breast cancer cells is related with tissue factor expression and procoagulant activity.

E. Mbemba¹, R. Amrane¹, N. Ferrand¹, M. Sabbah¹, P. Vandreden^{1, 2}, G. Gerotziafas¹, Presenter: G. Gerotziafas¹ (¹Paris, ²Genevilliers)
4
LMWH or DOACs for cancer associated thrombosis (CAT) in daily clinical practice ? – Insights from the GECAT registry

R. Klamroth¹, C. Pollich¹, H. Riess¹, M. Sinn², Presenter: R. Klamroth¹ (¹Berlin, ²Hamburg)
5
Anticoagulation practice of cancer-associated thrombosis in the outpatient sector of Germany

H. Riess¹, A. Kretzschmar², A. Heinken³, D. Mohebi⁴, M. May⁴, S. Schellong⁵, Presenter: H. Riess¹ (¹Berlin, ²Leipzig, ³Munich, ⁴Düsseldorf, ⁵Dresden)

18 - Oral Communication

Cancer-associated Thrombophilia

1:45 p.m. - 3:15 p.m., Rome

19 - Oral Communication

Cardiology & Neurology

1:45 p.m. - 3:15 p.m., Barcelona

Chair: Claudia Herrera Siklódy (Lausanne), Lorenz Hirt (Lausanne)

1
Current status of anti-thrombotic therapy in patients with atrial fibrillation undergoing PCI. Results of the prospective RIVA-PCI Registry.

U. Zeymer, Presenter: U. Zeymer (Ludwigshafen)
2
Anticoagulation for stroke prevention in patients with atrial fibrillation on hemodialysis is associated with net-clinical harm

O. Königsbrügge¹, H. Meisel¹, S. Schmaldienst¹, R. Klauser-Braun¹, M. Lorenz¹, M. Auinger¹, J. Kletzmayr¹, M. Hecking¹, W. Winkelmayer², I. Lang¹, I. Pabinger¹, M. Säemann¹, C. Ay¹, Presenter: O. Königsbrügge¹ (¹Vienna, ²Houston)
3
Red Cell Omega-3 FA Correlate with Reduced DDimer and Beta-Thromboglobulin as Markers of Coagulation Activation in Atrial Fibrillation

D. A. Bertschi¹, M. F. Reiner¹, J. Rutishauser¹, S. S. Saeedi², L. Werlen³, S. Aeschbacher³, S. Osswald³, D. Conen^{3, 4}, J. H. Beer^{1, 2}, Presenter: D. A. Bertschi¹ (¹Baden, ²Schlieren, ³Basel, ⁴Hamilton)
4
Growth differentiation factor-15 predicts major cardiac adverse events and all-cause mortality in patients with atrial fibrillation

S. Nopp, O. Königsbrügge, D. Kraemmer, I. Pabinger, C. Ay, Presenter: S. Nopp (Vienna)
5
WITHDRAWN - Regulation of platelet counts after myocardial ischemia and reperfusion injury

B. Tajdar, M. Klier, F. Reusswig, M. Elvers, Presenter: B. Tajdar (Düsseldorf)
6
Intracranial involvement and neurologic manifestations in Lemierre syndrome: analysis of 712 patients.

L. Valerio¹, T. F. Nicoletti², G. P. Corsi³, S. Granziera⁴, M. Jankowski¹, A. Pecci⁵, C. Sacco⁶, F. Zane⁷, S. V. Konstantinides^{1, 8}, S. Barco^{1, 9}, Presenter: L. Valerio¹ (¹Mainz, ²Rome, ³Bologna, ⁴Mestre, ⁵Pavia, ⁶Rozzano, ⁷Sondrio, ⁸Alexandroupolis, ⁹Zurich)

19 - Oral Communication

Cardiology & Neurology

1:45 p.m. - 3:15 p.m., Barcelona

20 - Oral Communication

Progress in Hemophilia Treatment

1:45 p.m. - 3:15 p.m., Sydney

Chair: Robert Klamroth (Berlin), Maria Martinez (Basel)

1
AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirms Stable FIX Expression and Sustained Reductions in Bleeding for up to 5 Years

W. A. Miesbach¹, K. Meijer², M. Coppens³, P. Kampmann⁴, R. Klamroth⁵, R. Schutgens⁶, G. Castaman⁷, E. Seifried⁸, J. Schwaeble⁸, H. Bönig⁹, E. K. Sawyer¹⁰, F. Leebeek¹¹, Presenter: W. A. Miesbach¹ (¹Frankfurt am Main, ²Groningen, ³Amsterdam, ⁴Copenhagen, ⁵Berlin, ⁶Utrecht, ⁷Florence, ⁸Wurttemberg-Hessen, ⁹Seattle, ¹⁰Lexington, ¹¹Rotterdam)
2
Gene Transfer with Etranacogene dezaparvovec (AAV5-Padua hFIX variant) in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial

W. A. Miesbach¹, A. Giermasz², G. Castaman³, N. S. Key⁴, S. U. Lattimore⁵, F. Leebeek⁶, A. von Drygalski⁷, M. Recht⁵, E. Gomez⁸, R. Gut⁹, S. W. Pipe¹⁰, Presenter: W. A. Miesbach¹ (¹Frankfurt am Main, ²Sacramento, ³Florence, ⁴Chapel Hill, ⁵Portland, ⁶Rotterdam, ⁷La Jolla, ⁸Phoenix, ⁹Lexington, ¹⁰Ann Arbor)
3
The Innovative Factor VIII Molecules HAT and HAT RI Overcome Impairments of Hemophilia A Therapy

P. Herbener, J. Daufenbach, K. Winterling, J. Schüttrumpf, S. Kistner, Presenter: P. Herbener (Dreieich)
4
Long-term Efficacy and Safety of Fitusiran in Participants with Hemophilia A and B: An Interim Analysis of the Phase 1/2 Open-Label Extension Study

C. Négrier¹, M. V. Ragni², K. J. Pasi³, S. W. Pipe⁴, I. Hegemann⁵, P. Chowdary³, T. Lissitchkov⁶, P. Georgiev⁷, Z. Qiu⁸, S. Poloskey⁸, S. Kichou⁹, B. Mei⁹, S. Andersson⁹, C. Sussebach¹⁰, Presenter: C. Négrier¹ (¹Lyon, ²Pittsburgh, ³London, ⁴Michigan, ⁵Zurich, ⁶Sofia, ⁷Plovdiv, ⁸New Jersey, ⁹Massachusetts, ¹⁰Germany)
5
Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Early Bleed Resolution for Persons with Hemophilia A or B with Inhibitors: Results of the randomized cross-over PERSEPT 1 phase 3 study

C. Hermans¹, W. Miesbach², M. Wang³, J. Ducore⁴, J. Journeycake⁵, M. Escobar⁶, D. Quon⁷, L. Boggio⁸, I. S. Mitchell⁹, A. Al-Sabbagh¹⁰, D. Bonzo¹⁰, W. A. Alexander¹¹, J. Mahlangu¹², Presenter: C. Hermans¹ (¹Brussels, ²Frankfurt, ³Aurora, Co, ⁴Sacramento, ⁵Oklahoma, ⁶Houston, TX, ⁷Los Angeles, Ca, ⁸Chicago, IL, ⁹Broomfield, CO, ¹⁰Framingham, MA, ¹¹Loiusville, KY, ¹²Johannesburg)
6
Second interim analysis results from the STASEY trial: A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors

V. Jiménez-Yuste¹, R. Klamroth², G. Castaman³, J. Kremer Hovinga⁴, C. Shanmukhaiah⁵, S. Rangarajan⁵, J. García Chavez⁶, R. Martinez⁶, G. Kenet⁷, S. Robson⁸, C. Schmitt⁸, O. Meier⁸, M. Ozelo⁹, Presenter: J. Kremer Hovinga⁴ (¹Madrid, ²Berlin, ³Florence, ⁴Bern, ⁵Mumbai, ⁶Mexico City, ⁷Ramat Gan, ⁸Basel, ⁹São Paulo)

20 - Oral Communication

Progress in Hemophilia Treatment

1:45 p.m. - 3:15 p.m., Sydney

21 - Plenary

Plenary 1 - T&H Across Borders

3:30 p.m. - 4:30 p.m., Rome

Chair: Johannes Oldenburg (Bonn)

Recent advances in gene therapy

Katherine High, Pennsylvania
New opportunities for diagnosis and prognosis of stroke: the benefits of across border approaches

Denis Vivien, Caen

21 - Plenary

Plenary 1 - T&H Across Borders

3:30 p.m. - 4:30 p.m., Rome

22 - State of the Art

Hemophilia

4:45 p.m. - 6:15 p.m., Rome

Chair: Inga Hegemann (Zurich), Martin Olivieri (Munich)

Modern treatment of hemophilia in children

Manuel Carcao, Toronto
How to deal with inhibitors

Andreas Tiede, Hannover
Patient-tailored hemophilia treatment

Claude Negrier, Lyon

22 - State of the Art

Hemophilia

4:45 p.m. - 6:15 p.m., Rome

23 - State of the Art

Hemato-oncology A

4:45 p.m. - 6:15 p.m., Barcelona

Chair: Bernhard Gerber (Bellinzona), Minna Voigtländer (Hamburg)

Hemostatic markers and prognosis in patients with cancer

Ingrid Pabinger-Fasching, Vienna
Primary thromboprophylaxis in ambulatory cancer patients

Alok Khorana, Cleveland
Management of disseminated intravascular coagulation in leukemia

Hugo ten Cate, Maastricht

23 - State of the Art

Hemato-oncology A

4:45 p.m. - 6:15 p.m., Barcelona

24 - State of the Art

News on Platelets

4:45 p.m. - 6:15 p.m., Sydney

Chair: Beate Kehrel (Münster), Barbara Zieger (Freiburg im Breisgau)

Modulating platelet reactivity by the crosstalk of protein kinase and phosphatase signaling pathways

Kerstin Jurk, Mainz
Regulation of platelet function by microRNAs

Pierre Fontana, Geneva
Platelets and matrix metalloproteinases: a complex interaction with multiple physiologic and pathologic implications

Paolo Gresele, Perugia

24 - State of the Art

News on Platelets

4:45 p.m. - 6:15 p.m., Sydney

25 - State of the Art

Cardiology - Neurology

4:45 p.m. - 6:15 p.m., Lausanne

Chair: Patrik Michel (Lausanne), Jan Steffel (Zurich)

DOACs in atrial arrhythmias: Current state of the art

Jan Beyer-Westendorf, Dresden
DOACs after ischemic stroke: Which patient? Which drug? And how early?

Gian Marco De Marchis, Basel
Reversing DOACs: Possibilities and usefulness

Sabine Eichinger-Hasenauer, Vienna

25 - State of the Art

Cardiology - Neurology

4:45 p.m. - 6:15 p.m., Lausanne

26 - State of the Art

Drug discovery

4:45 p.m. - 6:15 p.m., Seoul

Chair: Christian Heinis (Lausanne), Benny Sorensen (Cambridge)

Therapeutics from snake venoms

R Manjunatha Kini, Singapore
The biopharmaceutics (r)evolution in research and therapy: complement-targeted drugs as illustrative example

Daniel Ricklin, Basel
Chasing new therapeutics

Thomas Szucs, Basel

26 - State of the Art

Drug discovery

4:45 p.m. - 6:15 p.m., Seoul

27 - Satellite Symposium

Alexion Pharma Germany GmbH

6:30 p.m. - 8:00 p.m., Rome

Chair: Cihan Ay (Vienna)

Neue Perspektiven bei der Aufhebung der Antikoagulation bei Faktor Xa Inhibitor-assoziierten Blutungen

Begrüßung & Einführung

Cihan Ay, Vienna
Management von Faktor Xa-Inhibitor-assoziierten lebensbedrohlichen Blutungen – aktuelle Evidenzlage

Edelgard Lindhoff-Last, Frankfurt am Main
Aktivität von Faktor Xa Inhibitoren – wie soll getestet und interpretiert werden?

Wolfgang Korte, St. Gallen
Andexanet alfa – Patientenfälle und Erfahrungen aus dem klinischen Alltag

Ingrid Pabinger-Fasching, Vienna
Diskussion

Cihan Ay, Vienna

27 - Satellite Symposium

Alexion Pharma Germany GmbH

6:30 p.m. - 8:00 p.m., Rome

28 - Satellite Symposium

LEO Pharma GmbH

6:30 p.m. - 8:00 p.m., Barcelona

Chair: Florian Langer (Hamburg)

Thrombosemanagement bei Patienten mit GI-, GU- und Gyn-Tumoren („3G“) aus onkologischer Sicht

Abwägungen in der Therapieentscheidung aus Sicht des Hämostaseologen: Der CAT-Behandlungsalgorithmus

Florian Langer, Hamburg
Herausforderung aus Sicht des Onkologen für die Behandlung von Tumor & Thrombose - bei gastro-onkologischen Patienten

Ralf-Dieter Hofheinz, Mannheim
Herausforderung aus Sicht des Onkologen für die Behandlung von Tumor & Thrombose - bei uro-onkologischen Patienten

Axel S. Merseburger, Lübeck
Herausforderung aus Sicht des Onkologen für die Behandlung von Tumor & Thrombose - bei gyn-onkologischen Patienten

Hans-Joachim Lück, Hannover
Therapie und Thromboseprophylaxe onkologischer Patienten für den klinischen Alltag

Florian Langer, Hamburg

28 - Satellite Symposium

LEO Pharma GmbH

6:30 p.m. - 8:00 p.m., Barcelona

29 - Satellite Symposium

BioMarin Deutschland GmbH

6:30 p.m. - 8:00 p.m., Sydney

Chair: Johannes Oldenburg (Bonn)

Gene therapy –What do I need to know?

Opening

Johannes Oldenburg, Bonn
What’s new in clinical trials?

K. John Pasi, London
What happens in the liver?

Sylvia Fong, San Rafael
What does the patient need to know? – Facts and emotion

Sylvia von Mackensen, Hamburg
What is the patients’ experience?

Wolfgang Miesbach, Frankfurt am Main
What does that mean for me?

Robert Klamroth, Berlin
Panel discussion

29 - Satellite Symposium

BioMarin Deutschland GmbH

6:30 p.m. - 8:00 p.m., Sydney